Use of aromatase inhibitors in gynecology

References

• Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin. Cancer Res.7, 2620–2635 (2001).
   PubMed Web of Science ®Google Scholar
• Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br. J. Cancer90, 1733–1739 (2004).
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS, Brodie AMH, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J. Steroid Biochem. Mol. Biol.76, 199–202 (2001).
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS, Häusler A, Schieweck K, Lang M, Bowman R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol.37, 1021–1027 (1990).
   PubMed Web of Science ®Google Scholar
• Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer6, 187–195 (1999).
   PubMed Web of Science ®Google Scholar
• Lønning P, Pfister C, Martoni A, Zamagni C. Pharmacokinetics of third-generation aromatase inhibitors. Semin. Oncol.30(Suppl. 14), 23–32 (2003).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Pfister CU, Johnston SRD et al. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer. Breast6, 245 (1997).
   Google Scholar
• Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res.7, 1230–1236 (2001).
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M. Lønning PE. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J. Clin. Oncol.20, 751–757 (2002).
   PubMed Web of Science ®Google Scholar
• Geisler J, Helle S, Ekse D, Duong N, Evans D, Lonning P. Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting, J. Clin. Oncol.24, 570s (2006).
   Google Scholar
• Burstein HHJ. Aromatase inhibitor-associated arthralgia syndrome. Breast16(3), 223–234 (2007).
   PubMed Web of Science ®Google Scholar
• Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P. Aromatase inhibitors for breast cancer: different structures, same effects? Endocr. Relat. Cancer15(1), 27–36 (2008).
   PubMed Web of Science ®Google Scholar
• Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat. Rev.34(Suppl. 1), S3–S18 (2008).
   PubMed Web of Science ®Google Scholar
• Moudgal NR, Shetty G, Selvaraj N, Bhatnagar AS. Use of a specific aromatase inhibitor for determining whether there is a role for oestrogen in follicle/oocyte maturation, ovulation and preimplantation embryo development. J. Reprod. Fertil. Suppl.50, 69–81 (1996).
   PubMedGoogle Scholar
• Santen RJ, Samojlik E, Wells SA. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab.51, 473–477 (1980).
   PubMedGoogle Scholar
• Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J. Clin. Endocrinol. Metab.55, 718–722 (1982).
   PubMed Web of Science ®Google Scholar
• Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod. Technol.10, 244–247 (2000).
   Google Scholar
• Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril.75, 305–309 (2001).
   PubMed Web of Science ®Google Scholar
• Mitwally MFM, Casper RF. Aromatase inhibition improves ovarian response to follicle stimulating hormone in poor responders. Fertil. Steril.774, 776–780 (2002).
   Google Scholar
• Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum. Reprod.188, 1588–1597 (2003).
   Web of Science ®Google Scholar
• Mitwally MF, Casper RF. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J. Soc. Gynecol. Investig.11, 406–415 (2004).
   PubMedGoogle Scholar
• Mitwally MFM, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil. Steril.83(1), 229–231 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil. Steril.82(6), 1561–1563 (2004).
   PubMedGoogle Scholar
• Fatemi HM, Kolibianakis E, Tournaye H et al. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod. Biomed. Online75, 543–546 (2003).
   Google Scholar
• Al-Omari WR, Sulaiman WR, Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int. J. Gynaecol. Obstet.853, 289–291 (2004).
   Google Scholar
• Healey S, Tan SL, Tulandi T, Biljan MM. Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertil. Steril.806, 1325–1329 (2003).
   Google Scholar
• Mitwally MF, Casper RF, Diamond MP. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reprod. Biol. Endocrinol.3, 54 (2005).
   PubMedGoogle Scholar
• Requena A, Herrero J, Landeras J et al.; Reproductive Endocrinology Interest Group of Spanish Society of Fertility. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum. Reprod. Update14(6), 571–582 (2008).
   PubMed Web of Science ®Google Scholar
• Mitwally MFM, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for induction of ovulation. Am. J. Obstet. Gynecol.192, 381–386 (2005).
   PubMed Web of Science ®Google Scholar
• Forman R, Gill S, Moretti M, Tulandi T, Koren G, Casper R. Fetal safety of letrozole and clomiphene citrate for ovulation induction. J. Obstet. Gynaecol. Can.29(8), 668–671 (2007).
   PubMedGoogle Scholar
• Tulandi T, Martin J, Al-Fadhli R et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil. Steril.85(6), 1761–1765 (2006).
   PubMed Web of Science ®Google Scholar
• Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR, Bulun SE. Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil. Steril.69(4), 709–713 (1998).
   PubMed Web of Science ®Google Scholar
• Fatemi HM, Al-Turki HA, Papanikolaou EG, Kosmas L, DeSutter P, Devroey P. Successful treatment of an aggressive recurrent postmenopausal endometriosis with an aromatase inhibitor. Reprod. Biomed. Online11(4), 455–457 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int. J. Clin. Oncol.14(5), 378–382 (2009).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Crosignani PG, Somigliana E, Berlanda N, Barbara G, Fedele L. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum. Reprod.24(10), 2504–2514 (2009).
   PubMed Web of Science ®Google Scholar
• Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil. Steril.59, 511–515 (1993).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Trespidi L, DeGiorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain. Relation to disease stage and localization. Fertil. Steril.65, 299–304 (1996).
   PubMed Web of Science ®Google Scholar
• Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet. Gynecol. Scand.72, 324–336 (1993).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Fedele L, Bianchi S, Candiani GB. Pelvic denervation for chronic pain associated with endometriosis: fact or fancy? Am. J. Obstet. Gynecol.165, 745–749 (1991).
   PubMed Web of Science ®Google Scholar
• Wilson ML, Farquhar CM, Sinclair OJ, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst. Rev.2, CD001896 (2000).
   Google Scholar
• Gambone JC, Mittman BS, Munro MG, Scialli AR, Winkel CA. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil. Steril.78, 961–972 (2002).
   PubMed Web of Science ®Google Scholar
• Olive DL, Pritts EA. The treatment of endometriosis: a review of the evidence. Ann. N. Y. Acad. Sci.955, 360–372 (2002).
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Pisacreta A, Pesole AP, Vicentini S, Crosignani PG. Surgical management of endometriosis. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol.14, 501–523 (2000).
   PubMed Web of Science ®Google Scholar
• Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil. Steril.81, 1395–1398 (2004).
   PubMed Web of Science ®Google Scholar
• Razzi S, Fava A, Sartini A, De Simone S, Cobellis L, Petraglia F. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. Br. J. Obstet. Gynaecol.111, 182–184 (2004).
   Google Scholar
• Remorgida V, Abbamonte HL, Ragni N, Fulcheri E, Ferrero S. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil. Steril.88(3), 724–726 (2007).
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Casper RF, Diamond MP. Oestrogen-selective modulation of FSH and LH secretion by pituitary gland. Br. J. Cancer92(2), 416–417 (2005).
   PubMed Web of Science ®Google Scholar
• Dupont A, Dupont P, Belanger A, Mailoux J, Cusan L, Labrie F. Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2(10)]LH-RH ethylamide. Fertil. Steril.54, 227–232 (1990).
   PubMedGoogle Scholar
• Saito S, Murakami T, Suzuki K, Terada Y, Fukushima K, Moriya T. Intestinal endometriosis complicated by ileal perforation after initiation of gonadotropin-releasing hormone agonist therapy. Fertil. Steril.88, 969.e7–e9 (2007).
   Google Scholar
• Hall LLH, Malone JM, Ginsburg KA. Flare-up of endometriosis induced by gonadotropin-releasing hormone agonist leading to bowel obstruction. Fertil. Steril.64, 1204–1206 (1995).
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists. Fertil. Steril.91(4 Suppl.), 1574–1577 (2009).
   PubMed Web of Science ®Google Scholar
• Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception60, 173–175 (1999).
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Noguchi T, Amatsu T, Maeda K, Tsukamoto K, Yamamoto T. Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissue but not in normal endometrium. Biol. Reprod.57, 514–519 (1997).
   PubMed Web of Science ®Google Scholar
• Kimura F, Takahashi K, Takebayashi K et al. Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist. Fertil. Steril.87(6), 1468.e9–12 (2007).
   Google Scholar
• Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J. Clin. Endocrinol. Metab.78, 736–743 (1994).
   PubMed Web of Science ®Google Scholar
• Shozu M, Murakami K, Segawa T, Kasai T, Inoue M. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil. Steril.79, 628–631 (2003).
   PubMed Web of Science ®Google Scholar
• Attilakos G, Fox R. Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole. J. Obstet. Gynaecol.25, 609–610 (2005).
   PubMedGoogle Scholar
• Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod. Biomed. Online17(4), 569–574 (2008).
   PubMed Web of Science ®Google Scholar
• Rivera JA, Christopoulos S, Small D, Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J. Clin. Endocrinol. Metab.89, 3183–3188 (2004).
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Azmoon M, Alborzi S et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil. Steril.93(1), 192–198 (2009).
   PubMedGoogle Scholar
• Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune–Albright syndrome: a pilot study. J. Clin. Endocrinol. Metab.92(6), 2100–2106 (2007).
   PubMedGoogle Scholar
• Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune–Albright syndrome. J. Clin. Endocrinol. Metab.93(7), 2751–2754 (2008).
   PubMedGoogle Scholar
• Ailawadi R, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil. Steril.81, 290–296 (2004).
   PubMed Web of Science ®Google Scholar
• Razzi S, Fava A. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG81, 290–296 (2004).
   Google Scholar
• Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil. Steril.81, 1395–1398 (2004).
   PubMed Web of Science ®Google Scholar
• Soysal S, Soysal M, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrazole compared with goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum. Reprod.19, 160–167 (2004).
   PubMed Web of Science ®Google Scholar
• >Hefler L, Grimm C, van Trotsenburg M, Nagele F. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil. Steril.84, 1033–1036 (2005).
   Google Scholar
• Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil. Steril.84, 300–304 (2005).
   PubMed Web of Science ®Google Scholar
• Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet. Gynecol.109(6), 1421–1423 (2007).
   PubMed Web of Science ®Google Scholar
• Remorgida V, Abbamonte LH, Ragni N, Fulcheri E, Ferrero S. Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis. Aust. N. Z. J. Obstet. Gynaecol.47(3), 222–225 (2007).
   PubMed Web of Science ®Google Scholar
• Verma A, Konje JC. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients. Eur. J. Obstet. Gynecol. Reprod.143(2), 112–115 (2009).
   PubMed Web of Science ®Google Scholar
• Endometriosis: Current Management and Future Trends (1st Edition). Garcia-Velasco JA, Rizk BRMB (Eds). Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, India. Chapter 29, 244–256 (2010).
   Google Scholar